Introduction
Within a multi-celled organism, regulation and organization require that biological signals be transmitted from one cell to another, across cell membranes. Such is the case with growth factors, which originate from one site in an organism, yet need to be distributed throughout the organism to many cell types in order to exert their pleiotropic eects. Systems have evolved to allow a soluble signal, a growth factor for example, to be conveyed from the extracellular space to the cytoplasm and nucleus of a cell, thus directing protein synthesis, cellular growth, and cellular proliferation. To solve this problem of transmitting signals across membranes, growth factors appear to induce aggregation of their receptors, leading to activation of these receptors and signal propagation. Unregulated, however, these growth signals have the potential to promote inappropriate proliferation; receptor aggregation in the absence of signal represents a means of unregulated growth factor receptor activity which is postulated to occur in human neoplasia.
The neu gene encodes a 185-kDa transmembrane glycoprotein, referred to as p185neu, HER2, or erbB-2, possessing intrinsic protein tyrosine kinase activity. The receptor consists of an extracellular domain, with four subdomains including two cysteine rich domains, a transmembrane domain, and an intracellular domain, consisting of a juxtamembrane region, a tyrosine kinase domain, and a carboxyl tail harboring autophosphorylation sites (Figure 1 ). HER2 is homologous to, but distinct from, other members of the erbB family, which includes the epidermal growth factor receptor (EGFR or erbB-1), erbB-3, and erbB-4. The binding of cognate growth factors to these receptors regulates cell growth, proliferation, and dierentiation through the activation of receptor tyrosine kinases, triggering an incompletely de®ned signal transduction cascade. Signal transduction by these receptors is believed to involve dimerization and oligomerization, both in the form of homooligomers and hetero-oligomers in various erbB receptor combinations. Though this oligomerization has been recognized for more than 20 years, and though much progress has been made in de®ning the critical aspects of this process, many of the mechanistic principles involved remain to be de®ned. Key studies which have led to our current understanding of the mechanism and function of the oligomerization process in erbB receptors will be outlined below, as will the outstanding questions raised by these studies.
Mechanisms of dimerization/oligomerization
Though dimerization/oligomerization has been recognized as an integral component of signaling by erbB family receptors since shortly after the discovery of neu, the mechanism by which these receptors aggregate is still not fully understood. Extracellular, transmembrane, and intracellular domains of the protein have all been implicated in dimerization/oligomerization; the potential contribution of each of these domains to receptor aggregation will be discussed below.
Insights from the transmembrane domain
A role for neu in transformation and tumorigenesis has been suspected since its discovery as a dierentially expressed antigen in a chemically induced rat neuroglioblastoma (Padhy et al., 1982; Schechter et al., 1984; Shih et al., 1979 Shih et al., , 1981 , hence the name`neu'. Upon comparison of the normal, protooncogenic form of the gene with oncogenic neu in the rat model, a single causative point mutation in the putative transmembrane region of the protein revealed itself as the culprit lesion (Bargmann et al., 1986a,b) . Mutation occurred at position 664 of the protein sequence, encoding a change from the hydrophobic amino acid valine to the negatively charged glutamate. Further studies suggested that this mutation garnered its transforming eect by increasing the propensity of the receptor to form aggregates (Weiner et al., 1989b) . Although the mutation is not observed in human tumors, the information gained through the study of this mutation has provided invaluable clues to the mechanism of activation and transformation utilized by HER2/neu in human disease.
Early studies identi®ed that the eects of the point mutation seen in rat neu were mediated by dimerization. Using nondenaturing gel electrophoresis with cell lysates prepared from cells overexpressing normal or oncogenic (containing the transmembrane point mutation) forms of p185, Weiner et al. (1989a) found that the majority of oncogenic p185 existed in a dimeric form, while normal p185 was predominantly in a monomeric state. Co-transfection of short neu transmembrane sequences lacking both intracellular and extracellular domains was shown to diminish the transforming potential of full-length p185neu protein, presumably by preventing the formation of produc-tively arranged oligomers (Lofts et al., 1993) . Further supporting a role for oligomerization within the erbB family, EGFR dimerization had been demonstrated using chemical crosslinking (Fanger et al., 1989) , sucrose gradients (Boni-Schnetzler and Pilch, 1987) , and¯orescent energy transfer (Carraway et al., 1989) .
Though much eort has been expended toward de®ning the mechanism by which the observed transmembrane mutation leads to transformation, a clear answer has remained elusive. That this point mutation leads to increased dimerization, increased receptor tyrosine kinase activity, and increased transformation potential is well accepted; how this mutation leads to these eects remains a matter for debate. Three models have been proposed to explain the mechanism by which the transmembrane point mutation leads to oligomerization. The ®rst and second model, which dier only slighlty, favor stabilization of interreceptor transmembrane association via additional hydrogen bonds provided by the mutation; the ®rst model proposes that adjacent 664E residues interact, while the second proposes that the 664E residue interacts with the backbone of the adjacent receptor (Smith et al., 1996; Sternberg and Gullick, 1989) . Recent eorts in molecular modeling support these ®rst two models, but have not provided a means to distinguish between the two (Sajot and Genest, 2000) . Structural studies using NMR and IR have suggested that the 664E mutation is involved in a hydrogen bonding type of interaction with its partner transmembrane domain, supporting the ®rst model (Smith et al., 1996) . Mutational studies show that only Glu and Gln residues at position 664 lead to transformation, Asp and Tyr having weak eects, results consistent with a primary role for hydrogen bonding (Bargmann and Weinberg, 1988) . The third model proposes that the V664E mutation leads to a global conformational change within the transmembrane domain allowing for a more stable dimeric structure. Initially, molecular modeling and other structural analyses of the protooncogenic and oncogenic forms of the neu transmembrane domain suggested that the protooncogenic form of the receptor contained a kinked transmembrane domain, while the oncogenic form of the receptor was primarily helical (Brandt-Rauf et al., 1989 , 1995 . This model, however, has not been supported by later moleuclar dynamics simulations or other structural studies (Sajot and Genest, 2000; Smith et al., 1996) .
Because the transmembrane mutation seen in neu seems sucient to cause constitutive dimerization, a similar mutation in EGFR might be expected to lead to dimerization, unregulated signaling, and transformation. There exist con¯icting data on this point, however, bringing the autonomy of the transmembrane mutation into question. Simply mutating the equivalent Val in EGFR to Glu led to a receptor complex with increased, yet still ligand-dependent, transforming potential (Kashles et al., 1988) . A more recent study, however, found con¯icting results, suggesting that a point mutation in the EGFR transmembrane domain could lead to a ligand-independent transforming receptor complex (Beguinot et al., 1995) Production of a functional neu complex requires more than stable dimer formation, as a steric constraint on this dimerization also appears to be crucial. Experimentally relocating the position of the point mutation within the transmembrane domain only leads to a transforming receptor complex if the mutation is placed in certain positions. Bargmann and Weinberg (1988) noted that mutation of either residues 663 or 665, the residues immediately adjacent to the mutation observer in rat neu, to Glu did not lead to transformation. Other groups have pursued this observation, investigating the importance of residues surrounding the point mutation and more closely examining the location constraints for a transforming mutation (Burke et al., 1997; Cao et al., 1992) . By generating a battery of both random and rationally designed potential transmembrane sequences, Chen et al. (1997) found a critical limitation for spacing between residues with the potential for hydrogen bonding, suggesting a possible rotational constraint.
A transgenic mouse overexpressing protooncogenic erbB-2 develops tumors predominantly after spontaneous mutation of juxtamembrane residues, leading to disul®de-mediated constitutive dimerization (Siegel and Muller, 1996) . In addition to providing proof that dimerization leads to transformation, this observation Figure 1 Schematic diagram of structural organization of p185 receptors. Epidermal growth factor receptor (EGFR), Her2/neu/ erbB2, erbB3 and erbB4 are members of the super family. The numbers indicate the sequence homology among members compared to EGF receptor. They share a high degree of primary and tertiary structural homology in the tyrosine kinase domain and a moderate degree of homology in ectodomain. C-terminus is the most variable region among the receptors provided for the use of juxtamembrane mutations as a readily controlled arti®cial experimental system for the induction of dimerization (Sorokin et al., 1994) . Surprisingly, it was found that, depending on the location of the cysteine mutations introduced, stable dimers could be induced without concomitant transforation (Sorokin et al., 1994) , a result supported by a later study utilizing a transplanted dimerization-inducing transmembrane domain (Burke et al., 1997) . Upon further investigation, receptors with mutations that led to transforming receptor complexes all formed dimers involving the same predicted helical interface, strongly suggesting a steric constraint for p185neu activation (Burke and Stern, 1998) .
Extracellular domain
ErbB receptor extracellular domains are responsible ligand binding and seem to mediate dimerization/ oligomerization in the majority of biological settings. Natural variants and experimental mutations of these extracellular domains have provided clues to the nature of ligand binding and interaction of these domains. While other members in the receptor family have natural ligand, erbB2 has no known natural ligand to date. Despite an exhaustive search eort to ®nd a natural ligand, erbB-2 remains an orphan receptor, and it may very well be that this receptor functions mainly in complex with other family members. HER2/neu shows both ligand-independent and ligand-dependent activity, and investigation of each of these activities has provided valuable information regarding the mechanisms of transformation utilized by this receptor.
Ligand-dependent dimerization
Though erbB-2 is now thought to be an orphan receptor, it plays an active role in ligand-mediated signaling through heterodimerization with other erbB family members. Dimer formation between multiple erbB family members, in most combinations, in response to a growing list of ligands, constitutes a complex signaling network (Klapper et al., 2000; Tzahar et al., 1996) . The EGFR was the ®rst receptor tyrosine kinase proposed to dimerize in response to ligand binding (Yarden and Schlessinger, 1987a,b) , and this system has been well studied; an understanding of the ligand binding mechanism in EGFR should serve as a template for receptor ± ligand and receptor ± receptor interactions within the erbB family, and perhaps beyond. Ligand binding mechanisms utilized by other receptor families may also provide valuable clues to the mechanisms used within the erbB family. A general scheme based on current understanding of EGF induced oligomerization is shown in Figure 2 . Multiple studies have concluded that EGF binds EGFR with a 1 : 1 stoichiometry (Brown et al., 1994; Domagala et al., 2000; Lemmon et al., 1997; Odaka et al., 1997; Weber et al., 1984) . Subdomains I and especially III of the extracellular portion of EGFR have been identi®ed as important in ligand binding (Lax et al., 1998 (Lax et al., , 1989 Lee et al., 1995; Summer®eld et al., 1996) , as has subdomain IV, one of two cysteine rich domains (Saxon and Lee, 1999) . Recent structural modeling proposes that EGF binds in a cleft formed by subdomains I, II and III . Studies investigating the binding of EGF to EGFR show a high and a low anity binding site, and kinetic studies show that receptor activity is second order with respect to ligand (Canals, 1992) . In a recent study of EGF-sEGFR interactions, a complex binding mechanism has been observed, which could not be adequately described by a simple Langmuirian interaction (Domagala et al., 2000) . Two sEGFR populations have been detected in solution: one with a high anity (2 ± 20 nM) and the other with a low anity (400 ± 550 nM) for EGF (Domagala et al., 2000) . The results of these studies are complicated by the fact that some groups have used soluble receptor fragments, while others have used full-length receptor present on the surface of intact cells; the anity of EGF for a soluble extracellular EGFR fragment has been shown to be markedly lower than for the full-length receptor (Brown et al., 1994) . Furthermore, interpretation of binding studies with erbB receptors must take into account that the receptors are in a monomer/oligomer equilibrium which is not governed solely by ligand concentration. Using a soluble EGFR extracellular domain, positive cooperativity with increasing EGF concentration has been demonstrated (Hurwitz et al., 1991; Lemmon et al., 1997) , while studies of intact cells have demonstrated negative cooperativity (Chamberlin and Davies, 1998). Lemmon et al. (1997) investigating EGF-induced dimerization using soluble EGFR extracellular domain, proposed a model in which one EGF binds an EGFR monomer, followed by dimerization with a similar EGF/EGFR complex. One possibility assumes that the bound EGF molecule mediates subsequent dimerization; alternatively, EGF may bind to EGFR causing a conformational change favoring dimerization, without a requirement for EGF at the dimer interface (Green®eld et al., 1989; Lemmon et al., 1997) . While this model may accurately represent the events involved in ligand-induced oligomerization in solution, it may not re¯ect what is happening at the surface of intact cells.
A second model which could explain the observed high and low binding activities of EGF for EGFR involves the induction of dimerization by the binding of one EGF molecule to two EGFR, a low anity interaction, followed by the binding of a second EGF to the previously formed EGF : 2EGFR complex in which the EGFR now bind EGF with high anity. In such a model, high and low anity binding sites may be explained by the asymmetrical binding of a bivalent EGF in which each EGF binds with high anity to one member of the EGFR dimer and with low anity, via a distinct epitope, to a second EGFR (Summer®eld et al., 1996; Tzahar et al., 1997) ; a two binding site model is consistent with a recent structural model developed for the EGFR extracellular domain .
In support of this model, recent electron microscopic analysis suggests that EGFR may exist in a predimerized state, and that this state seems to correspond with observed high anity EGF binding sites (Gadella and Jovin, 1995) . A theoretical kinetic analysis proposed by Chamberlin and Davies (1998) which accounts for possible clustering that may occur on the surface of intact cells also supports a two site model in which EGF molecules bind sequentially. Recent singlemolecule imaging of EGFR on the cell surface (Sako et al., 2000) suggests that the predominant mechanism of dimerization involves the formation of a cell-surface complex of one EGF molecule and an EGFR dimer, followed by the direct arrest of a second EGF molecule. The EGFR dimers are thus preformed before the binding of the second EGF molecule.
Ligand-mediated binding involving erbB-2-containing heterodimers has not been as extensively studied as EGF/EGFR binding. Given the high degree of homology between erbB family members, models developed through the study of EGF/EGFR binding should prove a useful frame for understanding interactions within the erbB family. With respect to erbB-2 ligand-dependent dimerization, the data that exist suggest a model in which heterodimerization is mediated by ligand bivalence. ErbB-2 has been shown to be the preferred dimerization partner of the other erbB family members (Tzahar et al., 1996) , and demonstrates synergistic transforming eect when expressed with EGFR (Kokai et al., 1989) . Using soluble chimeric receptors, Jones et al. (1999) recently showed that heterodimerization with erbB2 enhances ligand binding for all other erbB family members to their respective ligands. Tzahar and colleagues (Tzaher et al., 1997) , in studies of erbB-2/erbB-3 heterodimerization driven by NDF/neuregulin, propose that NDF has a high anity interaction with erbB-3 and a low anity interaction with erbB-2, and that NDF simultaneously binds both receptors. Furthermore, this low anity binding site, while possessing relatively broad speci®city, may favor erbB-2 binding, providing a model which could explain the observed preference for heterodimerization and possibly even erbB-2 oncogenicity.
Ligand-independent dimerization
As discussed previously, the transmembrane mutation seen in rat neu confers the ability for ligandindependent signaling. Transmembrane mutation observed in rat is not seen in human tumors, probably because such a mutation would require a two nucleotide mutation in the human gene . Nevertheless if arti®cially introduced into human HER2/neu, an equivalent mutation leads to increased dimerization and transforming ability (Segatto et al., 1988) . Overexpression of the protooncogenic form of HER2/neu, however, either with or without ampli®cation, is observed in human tumors Klapper et al., 2000) . It might be expected, from data obtained with oncogenic neu, that increased dimerization/oligomerization, thus leading to increased signaling, would be seen in human tumors associated with HER2/neu overexpression; indeed, this turns out to be the case. In cell culture models, moderate overexpression (receptor number *10 5 ) of the protooncogenic form of p185, using an SV40 promoter-driven expression vector, failed to cause transformation in NIH3T3 cells. However, overexpression (receptor number 410 6 ) of this receptor at higher levels, using a retroviral promoter, was transforming (Di Fiore et al., 1987b; Di Marco et al., 1990) . Hence, it seems that once a critical threshold level of HER2/ neu expression is reached, transformation is achieved, a phenomenon thought to be due to spontaneous dimerization/oligomerization. To directly show that overexpression itself can lead to spontaneous oligomerization, we demonstrated that increasing the expression of protooncogenic p185neu shifted the receptor equilibrium from a monomeric to an aggregated state (Samanta et al., 1994 ). It appears that overexpression, much like the rat neu point mutation discussed previously, leads to unregulated oligomerization and unregulated signaling.
Extracellular domain of p185 is sucient to induce dimers. We have shown that mutant forms of p185neu lacking the intracellular portion of the receptor, both with and without the oncogenic transmembrane point mutation, are sucient to oligomerize with full-length EGFR and p185neu receptors (Qian et al., 1994a (Qian et al., ,b, 1996 . This binding is ligand-independent, and that truncated forms both with and without the oncogenic transmembrane point mutation eciently oligomerize suggests that this binding is mediated by the extracellular domain. In the reverse experiment, an intracellular truncation mutant of EGFR also heterodimerizes with p185neu (Kashles et al., 1991) , suggesting again that the extracellular domains of erbB receptors are sucient for dimerization.
Analysis of extracellular domain mutants derived from erbB-1 and erbB-2 have provided clues as to which subdomains are important for ligand binding and oligomerization. A truncated EGFR seen in human glioblastoma, for example, can dimerize and transform mammalian cells in a ligand-independent fashion (Moscatello et al., 1996) Homologous to mammalian erbB proteins, avian viral v-erbB truncation mutants display ligand-independent eects, though the signi®cance of the dimerization status of these proteins is unclear (Adelsman et al., 1996) . Herstatin, a recently discovered erbB-2 alternate transcript, consisting of 340 amino acids of the erbB-2 extracellular domain and 79 amino acids of novel sequence, binds full-length erbB-2, inhibiting its function (Doherty et al., 1999) . Studies with the deletion mutants suggest that the extracellular domains of erbB receptor that small structural components in a subdomain may function not only to mediate dimerization in response to ligand, but also to prevent surreptitious dimerization. Recently we have modeled the three dimensional structure of the erbB-2 extracellular domain using the HER2/Neu: mechanisms of dimerization/oligomerization PJ Brennan et al insulin-like growth factor-1 receptor (Garrett et al., 1998) as a template and found that the fourth domain may be critical for dimer formation. Based on this model, we have developed a small peptide with cystineknot topology which shows varying degree of anity to dierent members of erbB receptors. This small peptide is also able to block the dimer formation (Berezov, Murali and Greene, unpublished data). These results suggests that a relatively small fragment of the p185 extracellular domain has the ability to homodimerize.
Intracellular domain
Although the extracellular domain appears to be responsible for the majority of the interactions governing erbB receptor dimerization/oligomerization, evidence suggests that the intracellular domain plays more than a passive role in dimerization. For example, if both full-length EGFR and an intracellular domain truncated EGFR are coexpressed, full-length receptor favors binding available full-length receptor; this suggests that the intracellular domain may stabilize dimer formation (Kashles et al., 1991) .
To directly address the role of the intracellular domain in oligomerization, Chantry coexpressed truncated EGFR forms lacking the extracellular domain along with full-length receptor containing the intracellular domains of EGFR or HER2/neu, measuring the resultant dimerization, kinase activity, and autophosphorylation (Chantry, 1995) ; it was found that the intracellular domain, if membrane associated, was sucient for dimerization and kinase activation. Analysis of a panel of deletion mutants, created to ascertain which portions of the intracellular domain were involved in the observed dimerization, suggests that the kinase domain is critical. Interestingly, intracellular domain-mediated interactions were also observed between EGFR and PDGF receptor as well as HER2/neu and PDGF receptor, suggesting that dimerization may not be speci®c, but may represent interactions between`dimerization motifs' present within the highly conserved kinase domains of these receptors (Chantry, 1995) . The reverse experiment, however, in which the intracellular domain of p185 was expressed along with full-length EGFR, yielded con¯icting results, as an interaction was not seen (Qian et al., 1999) . Modeling from our laboratory nevertheless supports kinase domain interaction. Dimerization and tetramerization models of EGFR and p185 kinase domains suggest that these domains can associate as energetically stable structures (Murali et al., 1996) . In addition, the models suggest that the heterodimer interaction is more favorable than that of either homodimer, an observation which could contribute to observed synergistic signaling (Kokai et al., 1989) , and even to the favored binding partner status enjoyed by p185 (Graus-Porta et al., 1997; Tzahar et al., 1996) . The model also proposed dimerization of erbB receptors may be in¯uenced by electrostatic charge distribution near membrane proximal regions (Murali et al., 1996) . This hypothesis suggests that proper orientation of receptors is critical for dimerization. This feature has been observed in the EPO receptor complex (Livnah et al., 1998) .
Aggregation of erbB kinase domains seem to be intrinsically linked to their activity. Activation of kinase activity was observed in response to forced aggregation of a soluble EGFR intracellular domain by various methods, including cross-linking antibodies, polycation, or chemical reduction of protein solubility (Mohammadi et al., 1993) . Using a soluble version of the p185neu intracellular domain, we have shown that aggregation leads to an increase in the V max of the receptor (LeVea et al., 1993) . It is possible, then, that the binding activity inherent in the kinase domains of erbB and other growth factor receptors may serve to mediate interactions of these domains after extracellular domain-mediated juxtaposition, the end result being the same as with forced aggregation.
Functional consequences of oligomerization
It is clear that both homodimerization and heterodimerization occur within the erbB receptor tyrosine kinase family. To de®ne the function and the essential features of this phenomenon, a variety of receptor mutants have been generated, and their function subsequently evaluated both alone and in combination with other erbB receptors. The picture that has emerged suggests that oligomerization may allow kinase domains to be positioned next to one another, thereby allowing cross-phosphorylation, activation, and substrate phosphorylation. Several of the key experiment which have led to these conclusions are outlined below.
Homodimerization
Though the transforming activity of p185neu was identi®ed along with the receptor itself, and though receptor oligomerization was also quickly identi®ed as a feature of this receptor, the link between dimerization and transformation was not immediately accepted. The functional consequences of homodimerization of EGFR have also been studied, and this dimerization, which can be regulated by the presence or absence of ligand, has provided evidence in support of a role for homodimerization of erbB-2. Two possible mechanisms for the activation of EGFR signaling by EGF have been proposed; the ®rst suggests that EGF signal transmission occurs through a single EGFR monomer, possibly through an induced conformational change (Koland and Cerione, 1988) . The second, initially alternative hypothesis, supports a functional role for dimerization in ligand-responsive signal transduction (Yarden and Schlessinger, 1987b) . The kinetics of both dimerization and activation of full-length, solubilized EGFR were found to be second-order, with an identical rate constant, a correlation which strongly suggests that the two processes are linked (Canals, 1992) . EGFR has been shown to transform NIH3T3 cells when overexpressed, though this transformation is ligand-dependent (Di Fiore et al., 1987a ). An engineered EGFR mutant which no longer binds EGF with high anity, yet is constitutively dimerized, is transforming when expressed in NIH3T3 cells, suggesting that dimerization may be the critical function of ligand binding (Sorokin, 1995) .
Further evidence that the function of EGFR is dependent on dimerization/oligomerization has come Oncogene HER2/Neu: mechanisms of dimerization/oligomerization PJ Brennan et al from the use of antibodies. Cross-linking antibodies are capable of activating EGFR, an observation which has been documented by a number of groups using antibodies which recognize distinct epitopes of the EGFR extracellular domain (Schreiber et al., 1981; Spaargaren et al., 1991; Yarden and Schlessinger, 1987b) ; Non-crosslinking Fab fragments of these antibodies, however, do not activate the receptor (Spaargaren et al., 1991) . In contradiction with the above results, another antibody, capable of reducing EGFR dimerization, had little eect on EGFR autophosphorylation (Carraway and Cerione, 1993) .
As with the EGFR receptor, overexpression of erbB-2 at sucient levels transforms NIH3T3 cells (Di Fiore et al., 1987b) ; unlike the EGFR, however, this transformation is ligand-independent. As discussed previously, overexpression leads to spontaneous receptor oligomerization, and as with the EGFR receptor, oligomerization is thought to be necessary for signaling and subsequent transformation. In order to establish a role for oligomerization, and to de®ne the mechanism of activation and signaling utilized by erbB receptors, we and others have generated a variety of mutant forms of these proteins. A full-length kinase-inactive mutant of oncogenic neu, T757, when expressed in a background de®cient of both EGFR and erbB-2 proteins, retains the ability to oligomerize, yet is not transforming, indicating the critical importance of kinase activity to transformation (Qian et al., 1995) . Such a kinase-inactive mutant has been shown to have the ability to competitively inhibit the function of wildtype p185neu when co-expressed (Akiyama et al., 1991; Messerle et al., 1994) , likely by preventing the formation of productive dimers. TAPstop, a mutant in which the carboxy terminus has been truncated, including potential autophosphorylation sites, retains transforming ability, although at a reduced level compared to full-length p185neu. TD5, an ectodomain-deleted form of neu, also retains transforming ability, though like TAPstop, a lower level than p185neu.. Interestingly if either TAPstop or TD5 is coexpressed with the kinase-inactive mutant, T757, an increase in transforming potency is observed. While in cells expressing only T757, autophosphorylation of this mutant is not observed, double mutant cells contain T757 which has been phosphorylated at the carboxyl tail. Furthermore, the autophosphorylated T757 is capable of binding SH2-containing signal transduction proteins. These experiments suggest a model in which oligomerization allows trans-phosphorylation of binding partners which is dependent on the intrinsic kinase activity of the erbB receptor. That the introduction of a kinase-de®cient neu leads to an increase in transforming potency in the double mutant cell lines suggests that transformation may not be directly dependent on the intrinsic kinase activity of the erbB receptor, but rather on the docking of other signaling molecules at erbB autophosphorylation sites.
The critical aspect of erbB oligomerization may be juxtaposition of the kinase domains of binding partners. Studies of mutant neu forms in which the intracellular domain has been deleted, such as T691stop from our laboratory, support the notion that kinase domain interaction is critical. Coexpression of T691stop along with oncogenic neu results in a loss of transforming activity, the inhibition observed being dependent on the ratio of truncated and full-length receptor (Qian et al., 1996) . Stable dimers consisting of T691stop and p185neu are observed, and likely preclude the interaction of p185neu kinase domains, preventing transphosphorylation. The end result of this situation is the formation of dimers which do not contain phosphorylation-dependent docking sites, much the same as in cells expressing only kinaseinactive neu forms.
Heterodimerization of HER2/neu and EGFR
Early observations suggested that protooncogenic p185 activation is EGF dependent, despite that EGF does not bind p185, implying that EGFR may be involved in p185 signal transduction . Transformation by either protooncogenic p185 or EGFR alone requires high receptor expression; however, expression of both receptors at moderate levels is sucient to cause transformation (Kokai et al., 1989) , which is dependent on continuous cell surface expression of both receptors (Wada et al., 1990) . The apparent synergy in transformation observed with erbB-2 and EGFR may be particularly signi®cant, as these two receptors have been shown to be upregulated concomitantly in breast as well as other tumors Klapper et al., 2000) .
Investigating the link between p185 and EGFR signaling, our laboratory identi®ed a protein ± protein interaction between the two receptors using crosslinking reagents (Wada et al., 1990) . The observed interaction was found to be stimulated by EGF (Qian et al., 1992; Spivak-Kroizman et al., 1992; Wada et al., 1990) , though heterodimers were also detected in the absence of EGF (Qian et al., 1994a) . These results were con®rmed by non-denaturing gel electrophoresis, and the interactions found to be non-covalent in nature (Qian et al., 1992) . Heterodimerization of soluble extracellular domains of HER2/neu and EGFR has also been demonstrated (Spivak-Kroizman et al., 1992) . In addition to the two EGF anities observed for cells expressing only the EGFR, three anity states were identi®ed in cells expressing heterodimers, the additional anity state being higher than those observed with EGFR only (Wada et al., 1990) ; this suggests that oligomers which contain erbB-2 have a higher anity for ligand, an observation which has been con®rmed and extended to other erbB-2-containing erbB family heterodimers (Jones et al., 1999) . Heterodimers of EGFR and p185 are also formed preferentially over either homodimeric form (Qian et al., 1994b) , which may further contribute to their transforming potential.
Since this initial observation, a series of mutants have been constructted in order to investigate the functional interaction between p185neu and EGFR. When expressed with EGFR, a kinase-inactive HER2/ neu mutant, N757, was found to be trans-phosphorylated in and EGF-dependent fashion, suggesting that EGFR may be responsible for HER2/neu phosphorylation in the wild type oligomer (Qian et al., 1994b ). An intracellular truncation of p185, N691stop, also underwent EGF-dependent dimerization with EGFR, though the resulting complex was not active (Qian et al., 1994b) ; this suggests that activation is a transprocess, and that the absence of a binding partner precludes activation, auto or otherwise. These results provided evidence that erbB-2 is involved in the reciprocal activation of EGFR, showing that it is more than a mere substrate of the EGFR. Further studies with the N757 and N691stop mutants provide evidence for the functional importance of heterodimer formation; each of these mutations abolished the transformation and tumorigenicity seen with formation of the wild type heterodimer (Qian et al., 1994a) . The dominant-negative interaction of the truncated N691stop, eective in both cis and trans, could potentially be used therapeutically. T691stop, a version of this mutant with the transmembrane mutation observed in rat neu, binds in a ligandindependent fashion, and should therefore be an even more eective inhibitor of erbB receptor function. To test the therapeutic potential of this construct in a pathologic setting, O'Rourke et al. (1997) expressed T691stop in a cell line established from human glioblastoma; inhibition of transformation and tumorigenicity was observed.
The interactions observed between p185/EGFR heterodimers appear to be conceptually parallel to those observed with homodimers of either receptor. Similar to the studies outlined above, experiments have been done utilizing EGFR mutants, and the results are consistent with those obtained using mutant erbB-2 receptors. Coexpression of HER2/neu with an EGFR lacking most of the intracellular domain demonstrated that the kinase activity of HER2/neu could be inhibited in a trans-negative fashion, similar to the eects of the N691stop p185 mutant. Coexpression of a kinasede®cient EGFR with HER2/neu led to trans-phosphorylation of the mutant EGFR (Spivak-Kroizman et al., 1992) . Interestingly, tyrosine-phosphorylated dimers of kinase-de®cient EGFR were observed in these cells, which is surprising, given the inability of these receptors to trans-phosphorylate. It is possible that the receptors were phosphorylated as part of a larger HER2/neu-containing oligomeric complex. A second possibility which would explain this observation involves secondary dimerization, which involves an activated receptor dissociating from an oligomeric complex and subsequently phosphorylating a previously inactive receptor; this idea has been supported for erbB family proteins (Gamett et al., 1997).
Oligomerization
As discussed above, activation of erbB-2 receptors clearly involves the formation of dimeric receptor complexes, the dimer serving as the minimal functioning unit for erbB receptor signaling. Several lines of evidence, however, suggest that higher order aggregated structures, in addition to dimers, may function in erbB signaling. The idea that aggregation state may function in signal regulation is not novel; for example, it has been suggested that E. coli Tar receptor, which exists as a dimer, forms tetramers in its highest activity state (Cochran and Kim, 1996) . Though no de®nitive evidence has been produced demonstrating a functional role for higher-order aggregation states in the erbB family, the evidence which exists is extremely provocative. LeVea et al. (1993) working with the fulllength neu receptor generated in baculovirus, found that the transmembrane mutation led to an increase in aggregated receptor forms. In further studies using these puri®ed receptors, higher order oligomerization states were again observed (Samanta et al., 1994) . Similar results have been seen using soluble EGFR fragments, in which ligand-induced dimers and trimers were demonstrated after chemical crosslinking (Hurwitz et al., 1991) . Using a structure-based analysis, Lax et al. (1991) have also demonstrated the formation of dimers, trimers, and higher order oligomers using a soluble EGFR extracellular domain fragment. Though these results using puri®ed receptors are suggestive, there are obvious limitations to such in vitro studies.
Additional evidence for oligomerization comes from an early study into the kinetics of EGF binding to p185/EGFR heterodimers. As mentioned previously, Wada et al. (1990) described three binding anities for EGF in cells expressing both EGFR and p185. Monoclonal antibody treatment, led to the removal of p185 from the surface of the cells without aecting EGFR levels, as this antibody is thought to bind only to p185 homodimers. After treatment with this antibody, only two anity states remained. A possible model which could explain this binding behavior would predict that the high anity binding site was provided by a heterooligomeric complex consisting of two homodimers. The situation, however, is complex and would require further, more directed studies in order to con®dently draw such a conclusion.
More physiologically relevant data supporting receptor oligomerization has come from imaging studies of EGFR receptors, using both electron microscopy (van Belzen et al., 1988) and time-resolved¯uorescence imaging microscopy (Gadella and Jovin, 1995) . Fluorescence imaging microscopy suggests that EGF treatment quickly causes EGFR aggregation/clustering, and that a subset of EGFR receptors are pre-dimerized (Gadella and Jovin, 1995) . These studies raise the possibility that erbB signaling in intact cells, while requiring dimer formation, may actually be functionally activated by aggregation of receptor complexes, complexes which need not contain only members of the erbB family. Although no microscopic studies have directly addressed the aggregation of erbB-2 receptors, oligomerization would likely represent a general mechanism of activation within and likely beyond the erbB family, and thus its demonstration with any member of the erbB family would greatly support the importance of this phenomenon.
To further test the possibility that erbB protein can undergo higher order aggregation, we used molecular modeling to assess the energetic and structural feasibility of such a complex (Murali et al., 1996) . Modeling using the intracelluar domains of EGFR and p185neu predicts that a tetrameric complex with a 2 : 2 EGFR : p185neu stoichiometry would be energetically favorable. An interesting aspect of this model is the prediction that the interactions between subunits diers between the dimeric and the tetrameric forms; in the tetrameric form, the interactions are predicted to involve the autophosphorylation tyrosines. The possibility exists, then that tetramerization occurs only after dimerization and cross-phosphorylation, and that this transition is involved in signal regulation. Tetramerization/oligomerization could prove to be a central principle in receptor signaling, and its further investigation should prove fascinating.
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Conclusions and prospectus
Though much has been discovered regarding the mechanisms employed by the erbB family of receptors, many basic questions remain. An erbB crystal structure has been elusive, and though modeling insights have been helpful, crystallographic data would likely greatly advance current notions. Resolving the normal and tumorigenic receptor and ligand combinations involved in the erbB signaling network should also be of value. Additonally, although many candidate downstream signal transduction pathways have been identi®ed, the relative importance of each of these pathways to normal function and malignancy remains largely unknown.
Our current understanding of HER2/neu signaling has already translated into clinical success. That a threshold of HER2/neu overexpression is necessary for transformation suggested that any reduction in HER2/ neu signaling may lead to phenotypic reversion. Therapy directed toward this end, Herceptin, an anti-HER2/neu monoclonal antibody, has proven clinical eectiveness in the treatment of a subset of breast cancers (Shak, 1999) . Current and future research into the mechanisms by which HER2/neu promotes tumorigenesis will most likely lead to additional therapeutics. For example, since it appears that oligomerization is necessary for erbB signal transduction, agents capable of preventing oligomerization should also prevent signaling. Tumors which overexpress both HER2/neu and EGFR represent another clinical target, possibly involving bispeci®c antibodies directed at heterooligomers of these receptors. If future trends follow those that have already passed, further elucidation of erbB signaling should prove both scienti®cally and medically rewarding.
